

DAFTAR PUSTAKA

1. Yang AP, Liu J ping, Tao W qiang, Li H ming. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *Int Immunopharmacol.* 2020 Jul 1;84.
2. Baihaqi FA, Rumaropen H. Faktor-faktor yang berhubungan dengan lama rawat inap pasien COVID-19 di RSUD Serui Provinsi Papua: studi potong lintang. *J penyakit dalam Indones.* 2021;8(4):187-94
3. Prasetyoputri A, Dharmayanthi AB, Iryanto SB, Andriani A, Nuryana I, Wardiana A, *et al.* The dynamics of circulating SARS-CoV-2 lineages in Bogor and surrounding areas reflect variant shifting during the first and second waves of COVID-19 in Indonesia. *PeerJ.* 2022;10:1-12
4. WHO (2022). WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/>- Diakses Februari 2022
5. KEMENKES-RI (2022). Kementerian Kesehatan Republik Indonesia. <https://www.kemkes.go.id/>- Diakses Februari 2022
6. Website corona sumbar. <https://corona.sumbarprov.go.id/>- Diakses Februari 2022.
7. Peta Sebaran COVID-19 Indonesia. <https://covid19.go.id/id/peta-sebaran>- Diakses Oktober 2022
8. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, *et al.* Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect.* 2020;81(1):6–12.
9. Fu J, Kong J, Wang W, Wu M, Yao L, Wang Z, *et al.* The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. *Thromb Res.* 2020;192:3–8.
10. Kementerian Kesehatan Republik Indonesia. Manajemen Klinis Tata Laksana COVID-19 di Fasilitas Pelayanan Kesehatan. 2022: 11-21.
11. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgraduate Medical Journal.* 2021;97:312–20.
12. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, *et al.* Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis.* 2020;71(15):762–8.
13. Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. *Cell Biol Int.* 2020;44(9):1792–7.
14. Chen R, Sang L, Jiang M, Yang Z, Jia N. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. *J Allergy Clin Immunol.* 2020;146(1):89-100.
15. Hariyanto TI, Japar KV, Kwenandar F, Damay V, Siregar JI, Lugito NPH, *et al.* Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis.

- Am J Emerg Med. 2021;41:110–9.
16. Pirsalehi A, Salari S, Baghestani A, Vahidi M, Khave LJ, Akbari ME, *et al.* Neutrophil-to-lymphocyte ratio (NLR) greater than 6.5 May reflect the progression of COVID-19 towards an unfavorable clinical outcome. *Iran J Microbiol.* 2020;12(5):466–74.
 17. Pramana IGAASP, Masyuni PUS, Surawan IDP. Nilai rasio neutrofil-limfosit sebagai prediktor kasus COVID-19 serangan berat pada pasien dewasa. *Intisari Sains Medis.* 2021;12(2):530.
 18. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(4):844–7.
 19. Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay A, Seyit M, *et al.* D-Dimer as a potential biomarker for disease severity in COVID-19. *Am J Emerg Med.* 2021;40:55–9.
 20. Kurniati R, Abdullah F, Kam A. The profile of COVID-19 patients in Semen Padang Hospital Indonesia. *J.kesehat.Andalas.* 2021;10:45-48
 21. Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. *Expert Rev Clin Pharmacol.* 2021;14(5):601–21.
 22. Collaborators EM. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. *Lancet (London, England).* 2022;399(10334):1513–36.
 23. Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, *et al.* Aging in COVID-19 : Vulnerability , immunity and intervention. 2020;65:1-10
 24. Bergmann CC, Silverman RH. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. *Cleve Clin J Med.* 2020;87(5):321–7.
 25. Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, *et al.* COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. *J Pathol.* 2021 Jul;254(4):307-331.
 26. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol Endocrinol Metab.* 2020;318:735-41
 27. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Med.* 2020;46(8):1603–6.
 28. Listyoko AS, Djajalaksana S, Astuti T. Hubungan merokok dengan derajat keparahan dan mortalitas pasien COVID-19 rawat inap di RS Saiful Anwar Malang. *Medica Hosp J Clin Med.* 2020;7(1A):137–43.
 29. Khalafallah AA, Ibraheem A-RO, Teo QY, AlBarzan A-M, Parameswaran R, Hooper E, *et al.* Review of management and outcomes in women with thrombophilia risk during pregnancy at a single institution. *ISRN Obstet*

- Gynecol. 2014;2014:1–6.
30. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - J Am Med Assoc.* 2020;324(8):782–93.
 31. Burhan E, Susanto AD, Nasution SA, Eka G, Pitoyo ceva W, Susilo A, *et al.* Pedoman tatalaksana COVID-19 edisi 4. 2022:79–85.
 32. PDPI. Panduan Praktik Klinis: Pneumonia Covid-19. *J Am Pharm Assoc.* 2020;55(5):1–67.
 33. Safiabadi Tali SH, LeBlance JJ, Sadiq J. Tools and techniques for severe acute respiratory syndrome. *Clin Microbiol Rev.* 2021;34(3):228-91
 34. Sharma A, Balda S, Apreja M, Kataria K, Capalash N, Sharma P. COVID-19 diagnosis: current and future techniques. *Int J Biol Macromol.* 2021;193:1835–44
 35. Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, *et al.* Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. *Eur J Med Res.* 2020;25(1):1–10.
 36. Kelly KM, Burkhardt B, Bollard CM. Hematology: basic principles and practice. Philadelphia: Elsevier; 2018. p.1330-42.
 37. Lazarus HM, Schmaier AH. Concise guide to hematology. Cham:Springer Nature; 2019. p.209-21
 38. Prihatni D, Kosasih A, Parwati I. Rentang nilai normal hematologi penduduk Indonesia dewasa. In: Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indoneasia. 2019. p.12–3.
 39. Zhang J, Cao Y yuan, Tan G, Dong X, Wang B chen, Lin J, *et al.* Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. *Allergy Eur J Allergy Clin Immunol.* 2021;76(2):533–50.
 40. Yan X, Li F, Wang X, Yan J, Zhu F, Tang S, *et al.* Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. *J Med Virol.* 2020;92(11):2573–81.
 41. Nugroho A, Suwarman, Nawawi AM. Hubungan antara rasio neutrofil-limfosit dan skor sequential organ failure assesment pada pasien yang dirawat di ruang intensive care unit. *JAP.* 2013;1(3):189–96.
 42. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. *Crit Rev Clin Lab Sci .* 2020;0(0):389–99.
 43. Bastuga A, Erdoganb HB, Gokcinarc S, Kazancioglu D, Kosovalie S, Ozbayd BD, *et al.* Clinical and laboratory features of COVID-19 : predictors of severe prognosis Aliye Bastug. *J.intimp.* 2020;88:1-7.

44. Panduan Pemeriksaan Laboratorium COVID-19. In: Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indonesia. 2020. p. 3–5.
45. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, *et al.* Developmental haemostasis. Impact for clinical haemostasis laboratories. *Thromb Haemost.* 2006;95(2):362–72.
46. Berger JS, Kunichoff D, Adhikari S, Ahuja T, Amoroso N, Aphinyanaphongs Y, *et al.* Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients with COVID-19. *Arterioscler Thromb Vasc Biol.* 2020;8:2539–47.
47. Triyadi A, Muhiddin RA, Abdullah AA. Analysis of d-dimer levels in deep vein thrombosis patients. *Indones J Clin Pathol Med Lab.* 2020;26(2):198–202.
48. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular. *Int.J. Hematol.* 2020;113:45-57
49. Willim HA, Hardigaloeh AT, Supit AI. Koagulopati pada Coronavirus Disease-2019 (COVID-19): Tinjauan pustaka. *Intisari Sains Medis.* 2020;11(3):749–56.
50. Yu H, Qin C, Chen M, Wang W, Tian D. D-dimer level is associated with the severity of COVID-19. 2020;1:219-24.
51. Dahlan MS. Statistik untuk Kedokteran dan Kesehatan: Deskriptif, Bivariat, dan Multivariat, Dilengkapi Aplikasi dengan Menggunakan SPSS; 2013. p. 159.
52. Asghar MS, Khan NA, Haider Kazmi SJ, Ahmed A, Hassan M, Jawed R, *et al.* Hematological parameters predicting severity and mortality in COVID-19 patients of Pakistan: a retrospective comparative analysis. *J Community Hosp Intern Med Perspect.* 2020;10(6):514–20.
53. Bintoro SUY, Dwijayanti NMI, Pramudya D, Amrita PN, Romadhon PZ, Asmarawati TP, *et al.* Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia. *F1000Research.* 2021;10:791.
54. Jang JG, Hur J, Choi EY, Hong KS, Lee W, Ahn JH. Prognostic factors for severe coronavirus disease 2019 in Daegu , Korea. *J Korean Med Sci.* 2020;35:1–10.
55. Alwani M, Yassin A, Al-Zoubi RM, Aboumarzouk OM, Nettleship J, Kelly D, *et al.* Sex-based differences in severity and mortality in COVID-19. *Rev Med Virol.* 2021;31(6).
56. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, *et al.* Characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A Descript study. *Lancet.* 2020;395(10223):507–13.
57. Sutningsih D, Azzahra NA, Prabowo Y, Sugiharto A, Wibowo MA, Lestari ES, *et al.* Covid-19 deaths and associated demographic factors in Central

- Java, Indonesia. *Germes*. 2021;11(2):255–65.
58. Mukherjee S, Pahan K. Is COVID-19 Gender-sensitive?. *J Neuroimmune Pharmacol*. 2021;38–47.
 59. Brier J, lia dwi jayanti. COVID-19 and Sex Differences: Mechanisms and Biomarkers. *Mayo Clin Proc*. 2020;21(1):1–9.
 60. Djaharuddin I, Munawwarah S, Nurulita A, Ilyas M, Ahmad N. Comorbidities and mortality in COVID-19 patients. *Gac Sanit*. 2021; 35(S2):530–2
 61. Kraemer MUG, Yang CH, Gutierrez B, Wu CH, Klein B, Pigott DM, *et al*. The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* 368. 2020;368(6490):493–7.
 62. Yamada T, Wakabayashi M, Yamaji T, Chopra N. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis. *Clin Chim Acta*. 2020;509:235-243
 63. Pujani M, Raychaudhuri S, Verma N, Kaur H, Agarwal S, Singh M, *et al*. Association of Hematologic biomarkers and their combinations with disease severity and mortality in COVID-19- an Indian perspective. *Am J Blood Res*. 2021;11(2):180–90.
 64. Sinurat TR, Dinutanayo W, Aditya AP. Perbandingan derajat keparahan terhadap jumlah neutrofil, limfosit dan neutrophile to lymphocyte ratio (NLR) pada pasien COVID-19. *JKesVo*. 2022;134–9.
 65. Kalabin A, Raj V, Mani K, Valdivieso SC, Donaldson B. Role of neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios as predictors of disease severity in COVID-19 patients. *InfezMed*. 2021;1:46–53.
 66. Simadibrata DM, Calvin J, Wijaya AD, Arkan N, Ibrahim A. Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients : A meta-analysis. *AJEM*. 2021;42:60-9.
 67. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, *et al*. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clin Chim Acta*. 2020;507:174–80.
 68. Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, *et al*. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. *JCI Insight*. 2020;5(10):1–11.
 69. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, *et al*. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. *BMJ*. 2020;368.
 70. Wei Y, Zeng W, Huang X, Li J, Qiu X, Li H, *et al*. Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: A single-center descriptive study. *BMC Infect Dis*. 2020;20(1):1–10.

71. Hilda F, Liana P, Nurtjahyo A, Hudari H, Sari NP, Umar TP, *et al.* D-dimer as a sensitive biomarker of survival rate in patients with. *Eurasian J Med.* 2022;54(3):219–24.
72. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, *et al.* Biomarkers and outcomes of COVID-19 hospitalisations: Systematic review and meta-analysis. *BMJ Evidence-Based Med.* 2021;26(3):107–8.
73. Du WN, Zhang Y, Yu Y, Zhang RM. D-dimer levels is associated with severe COVID-19 infections: A meta-analysis. *Int J Clin Pract.* 2021;75(8):1–5.

